Full warehouse, high margin and a good perspective of profitability ᅠ.
In the 9 months that ended in Sharibar 1405, Suban Daro recorded a net profit of about 2.9 MET with sales of 6.3 MET and a gross profit of 68%. This figure is 5.5 times the total profit of 1404 (530 billion tomans) and 74% of the annual budget of 4 Hemati. For the entire fiscal year ending in Ezer, assuming a drop in gross profit to 63%, the profit is estimated at 4.7 Hamat (465 Tomans per share). The company has about 4 months of raw materials in the warehouse and according to the advance payments it has another 4 to 5 months in customs. For this reason, even in the worst case and without a special rate increase, the gross profitability is around 50%, and with these stocks it can be between 60 and 70%. The 1406 estimate does not include expansion plans, including a new packaging machine that will add 20% to capacity. With a rate increase of 50%, next year's profit will be 7.3 MT with a 60% margin and 8 MT with a 65% margin. In the worst case scenario, i.e. a margin of 50%, this number is about 5.9 MT. The claim collection period also increased from 333 days to 185 days. The stock has returned 623% since the market opened and is well ahead of both the pharmaceutical industry index (285%) and the overall index (113%), although it has corrected 15% in the past week. Overall, with this inventory and this profit margin, Desabahan is one of the best drugs in the market.
ᅠ Value investment.
ᅠ.